Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing
Hangzhou Qihan Biotech Co., Ltd. today announced the successful completion of a pre-Series B financing exceeding $16 million.
Qihan Biotech Appoints Naxin Yao to its Board of Directors
Qihan Biotech today announced the appointment of Mr. Naxin Yao to its Board of Directors as an independent director.
Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma
Qihan Biotech Appoints Tony W. Ho to its Board of Directors
Qihan Biotech today announced the appointment of Tony W. Ho, M.D., to its Board of Directors as an independent director.
Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2022
NK cells derived from genetically engineered human induced pluripotent stem cells (iPSCs) hold great potential to become the next generation allogeneic cell therapy products.
Luhan Yang & George Church: Ten billion dollars should be spent on anti-aging research
Qihan Biotech Raises Additional USD 67 Million in Series A++ Financing. Funds to Advance Pipeline of Novel Cell and Organ Therapies
Qihan Biotech Co. Ltd announced today that it has raised an additional $67 million in Series A++ financing. With these investments, Qihan’s total Series A financing raised to date has exceeded $100 million.
Best wishes for the Spring Festival from the Scientific Advisory Board of Qihan
Happy new year!
Luhan Yang-Lecture of Harvard CSSA
Harvard Chinese Students and Scholars Association